image
Phibro Animal Health Corporation PAHC
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
Watchlist
$ 18.66
-2.76 %
$ 756 M
Market Cap
38.88
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one PAHC stock under the worst case scenario is HIDDEN Compared to the current market price of 18.7 USD, Phibro Animal Health Corporation is HIDDEN

PAHC Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one PAHC stock under the base case scenario is HIDDEN Compared to the current market price of 18.7 USD, Phibro Animal Health Corporation is HIDDEN

PAHC Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one PAHC stock under the best case scenario is HIDDEN Compared to the current market price of 18.7 USD, Phibro Animal Health Corporation is HIDDEN

PAHC Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart PAHC

image
1M -17%
6M -29.0%
1Y 44%
3Y 7.0%
5Y -9%
All
$27.0$27.0$26.0$26.0$25.0$25.0$24.0$24.0$23.0$23.0$22.0$22.0$21.0$21.0$20.0$20.0$19.0$19.0$18.0$18.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
1.02 B REVENUE
4.07%
Growth Rates
1Year 4.07%
3Years 6.89%
5Years 4.21%
7Years 4.18%
10Years 3.93%
53.3 M OPERATING INCOME
-25.79%
Growth Rates
1Year -25.79%
3Years 7.42%
5Years -6.17%
7Years -8.32%
10Years -1.78%
2.42 M NET INCOME
-92.59%
Growth Rates
1Year -92.59%
3Years -64.58%
5Years -46.42%
7Years -37.47%
10Years 10.74%
87.6 M OPERATING CASH FLOW
558.11%
Growth Rates
1Year 558.11%
3Years 21.94%
5Years 13.18%
7Years -1.65%
10Years 62.07%
-48.2 M INVESTING CASH FLOW
34.89%
Growth Rates
1Year 34.89%
3Years -37.40%
5Years -27.81%
7Years -11.93%
10Years -9.52%
-6.77 M FINANCING CASH FLOW
-25.08%
Growth Rates
1Year -25.08%
3Years 26.43%
5Years -10.51%
7Years 25.62%
10Years -9.22%
309 M REVENUE
18.75%
Growth Rates
1Year 4.07%
3Years 6.89%
5Years 4.21%
7Years 4.18%
10Years 3.93%
25.5 M OPERATING INCOME
44.26%
Growth Rates
1Year -25.79%
3Years 7.42%
5Years -6.17%
7Years -8.32%
10Years -1.78%
3.18 M NET INCOME
-54.34%
Growth Rates
1Year -92.59%
3Years -64.58%
5Years -46.42%
7Years -37.47%
10Years 10.74%
3.08 M OPERATING CASH FLOW
-75.63%
Growth Rates
1Year 558.11%
3Years 21.94%
5Years 13.18%
7Years -1.65%
10Years 62.07%
-260 M INVESTING CASH FLOW
-8789.86%
Growth Rates
1Year 34.89%
3Years -37.40%
5Years -27.81%
7Years -11.93%
10Years -9.52%
276 M FINANCING CASH FLOW
1046.40%
Growth Rates
1Year -25.08%
3Years 26.43%
5Years -10.51%
7Years 25.62%
10Years -9.22%
Balance Sheet Phibro Animal Health Corporation
image
Current Assets 601 M
Cash & Short-Term Investments 115 M
Receivables 169 M
Other Current Assets 317 M
Non-Current Assets 381 M
Long-Term Investments 11.5 M
PP&E 241 M
Other Non-Current Assets 129 M
11.67 %17.25 %32.27 %24.53 %13.11 %Total Assets$982.2m
Current Liabilities 204 M
Accounts Payable 85.6 M
Short-Term Debt 37.3 M
Other Current Liabilities 81.3 M
Non-Current Liabilities 521 M
Long-Term Debt 488 M
Other Non-Current Liabilities 33.2 M
11.79 %5.13 %11.21 %67.29 %4.57 %Total Liabilities$725.5m
EFFICIENCY
Earnings Waterfall Phibro Animal Health Corporation
image
Revenue 1.02 B
Cost Of Revenue 705 M
Gross Profit 313 M
Operating Expenses 260 M
Operating Income 53.3 M
Other Expenses 50.9 M
Net Income 2.42 M
1b1b1b1b800m800m600m600m400m400m200m200m001b(705m)313m(260m)53m(51m)2mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
30.77% GROSS MARGIN
30.77%
Averages
1Year 30.77%
3Years 30.52%
5Years 31.24%
7Years 31.53%
10Years 31.66%
5.24% OPERATING MARGIN
5.24%
Averages
1Year 5.24%
3Years 5.83%
5Years 5.45%
7Years 6.88%
10Years 8.41%
0.24% NET MARGIN
0.24%
Averages
1Year 0.24%
3Years 2.93%
5Years 3.90%
7Years 4.86%
10Years 6.15%
0.94% ROE
0.94%
Averages
1Year 0.94%
3Years 10.41%
5Years 14.37%
7Years 18.89%
10Years 46.99%
0.25% ROA
0.25%
Averages
1Year 0.25%
3Years 2.96%
5Years 3.92%
7Years 5.26%
10Years 7.29%
1.45% ROIC
1.45%
Averages
1Year 1.45%
3Years 3.60%
5Years 3.85%
7Years 6.04%
10Years 9.33%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Phibro Animal Health Corporation
image
80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 2.42 M
Depreciation & Amortization 36.2 M
Capital Expenditures -41.2 M
Stock-Based Compensation 475 K
Change in Working Capital 33.1 M
Others 50.4 M
Free Cash Flow 46.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Phibro Animal Health Corporation
image
Wall Street analysts predict an average 1-year price target for PAHC of $18.7 , with forecasts ranging from a low of $17 to a high of $21 .
PAHC Lowest Price Target Wall Street Target
17 USD -8.90%
PAHC Average Price Target Wall Street Target
18.7 USD 0.04%
PAHC Highest Price Target Wall Street Target
21 USD 12.54%
Price
Max Price Target
Min Price Target
Average Price Target
282826262424222220201818161614141212May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.57% DIVIDEND YIELD
0.12 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
0.500.500.450.450.400.400.350.350.300.300.250.250.200.200.150.150.100.100.050.050.000.000.10.10.10.10.120.120.120.120.120.120.120.10.10.10.10.120.120.120.120.120.120.10.10.10.10.120.120.120.120.120.120.10.400.10.400.10.400.120.420.120.480.120.480.120.480.120.480.120.480.120.480.122015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 6
6. Ownership
Insider Ownership Phibro Animal Health Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
110 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
100 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
PAHC vs. BSX: Which Stock Is the Better Value Option? Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks? zacks.com - 2 weeks ago
Is Phibro Animal Health (PAHC) Stock Undervalued Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 2 weeks ago
3 Undervalued MedTech Stocks to Buy for 2025 Gains Amid S&P 500 Rally Three discounted MedTech stocks to gain from the market rebound are PAHC, FMS and INMD. zacks.com - 3 weeks ago
Should You Bet on PAHC Stock at a Discounted P/E of 10.41X? PAHC's solid MFA franchise, now bolstered by Zoetis' portfolio, makes it a solid investment case. A well-established foothold in key regions is also a factor. zacks.com - 3 weeks ago
Looking for a Growth Stock? 3 Reasons Why Phibro (PAHC) is a Solid Choice Phibro (PAHC) possesses solid growth attributes, which could help it handily outperform the market. zacks.com - 3 weeks ago
PAHC vs. BSX: Which Stock Should Value Investors Buy Now? Investors with an interest in Medical - Products stocks have likely encountered both Phibro Animal Health (PAHC) and Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now? zacks.com - 1 month ago
Is Phibro Animal Health (PAHC) a Great Value Stock Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 1 month ago
Phibro Animal Health Stock Up 87.5% in a Year: What's Driving the Rise? PAHC stays on investors' radar due to its Animal Health business and potential in emerging markets. zacks.com - 1 month ago
Why Is Phibro (PAHC) Down 5.2% Since Last Earnings Report? Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? zacks.com - 1 month ago
Phibro Animal Health Corporation to Participate at Barclays Annual Global Healthcare Conference TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Barclays Annual Global Healthcare Conference. Chief Financial Officer, Glenn David will address financial analysts and investors on Thursday, March 13, 2025, at 9:00 AM ET at the Loews Miami Beach Hotel. The live audio presentation will be available on the Phibro Animal Health Corporation Investor Relations Website at https://investors.pahc.com. A replay of the session will. businesswire.com - 1 month ago
Here's Why Phibro Animal Health (PAHC) is a Strong Value Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com - 1 month ago
Is PAHC Stock a Smart Addition to Your Portfolio Right Now? Phibro's robust performance in the Animal Health business and prospects in the emerging markets are highly encouraging. zacks.com - 1 month ago
8. Profile Summary

Phibro Animal Health Corporation PAHC

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 756 M
Dividend Yield 0.57%
Description Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It operates in the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 2014 and is headquartered in Teaneck, New Jersey.
Contact Glenpointe Centre East, Teaneck, NJ, 07666-6712 https://www.pahc.com
IPO Date April 11, 2014
Employees 1940
Officers Mr. Larry L. Miller Chief Operating Officer Ms. Judith A. Weinstein Senior Vice President, General Counsel & Corporate Secretary Mr. Jonathan Bendheim Executive Vice President of Global Technology & People and Director Ms. Lisa A. Escudero Senior Vice President of Human Resources Mr. Daniel M. Bendheim J.D. Executive Vice President of Corporate Strategy & Director Mr. Ramon Fuenmayor President South America Region Mr. Rob Aukerman Advisor Mr. Jack Clifford Bendheim Chairman, President & Chief Executive Officer Mr. Glenn C. David Chief Financial Officer Mr. Samson Li President of Asia Pacific Region